Polycationic peptide guided spherical ordered self-assembly of biomacromolecules

Biomaterials

Volumn 33, Issue 33, 2012, Pages 8723-8732

  Shi, Kai ^a   Cui, Fude ^a   Bi, Hongshu ^b   Jiang, Yanbo ^a   Song, Tao ^c  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Liaoning Yilian Institute of Materia Medica   (China)

^c Liaoning Satellite Biotechnology Products Research Institute   (China)

Author keywords

Biomacromolecule; Controllable delivery; Interferon; Polycationic peptide; Self assembly

Indexed keywords

BIOLOGICAL POTENCY; BIOMACROMOLECULE; BIOMACROMOLECULES; BLOOD LEVELS; CONTROLLABLE DELIVERY; DISSOLUTION BEHAVIOR; DURATION TIME; IN-VITRO; MOLAR RATIO; MOLECULAR ENTITIES; MOLECULAR SELF ASSEMBLY; MOLECULAR SIMULATIONS; OPTIMAL REGIONS; ORDERED GROWTH; PHYSICO-CHEMICAL CHARACTERIZATION; POLYCATIONIC PEPTIDES; SEMICRYSTALLINES; THERAPEUTIC PROTEIN; THREE-DIMENSIONAL ORDERED STRUCTURES;

BINDING SITES; INTERFERONS; PEPTIDES; PHASE DIAGRAMS; SPHERES; X RAY DIFFRACTION;

SELF ASSEMBLY;

PEPTIDE; POLYCATIONIC PEPTIDE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT HUMAN INTERFERON ALPHA2B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOMACROMOLECULE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CONFORMATION; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; MACROMOLECULE; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE; X RAY DIFFRACTION;

CIRCULAR DICHROISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON-ALPHA; PEPTIDES; POLYAMINES; RECOMBINANT PROTEINS; X-RAY DIFFRACTION;

EID: 84866152212     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.08.037     Document Type: Article

References (34)

1. Fu K., Klibanov A.M., Langer R. Protein stability in controlled-release systems. Nat Biotechnol 2000, 18:24-25.
2. Putney S.D., Burke P.A. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 1998, 16:153-157.
3. Sinha V.R., Trehan A. Biodegradable microspheres for protein delivery. J Control Release 2003, 90:261-280.
4. Gokarn Y.R., McLean M., Laue T.M. Effect of PEGylation on protein hydrodynamics. Mol Pharm 2012, 9:762-773.
5. Bailon P., Won C.Y. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009, 6:1-16.
6. Basu S.K., Govardhan C.P., Jung C.W., Margolin A.L. Protein crystals for the delivery of biopharmaceuticals. Expert Opin Biol Ther 2004, 4:301-317.
7. Jen A., Merkle H.P. Diamonds in the rough: protein crystals from a formulation perspective. Pharm Res 2001, 18:1483-1488.
8. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007, 282:20047-20051.
9. Ritchie D.W. Recent progress and future directions in protein-protein docking. Curr Protein Pept Sci 2008, 9:1-15.
10. Rajagopal K., Schneider J.P. Self-assembling peptides and proteins for nanotechnological applications. Curr Opin Struct Biol 2004, 14:480-486.
11. Zhang S. Fabrication of novel biomaterials through molecular self-assembly. Nat Biotechnol 2003, 21:1171-1178.
12. Rogers S.S., Krebs M.R., Bromley E.H., van der Linden E., Donald A.M. Optical microscopy of growing insulin amyloid spherulites on surfaces in vitro. Biophys J 2006, 90:1043-1054.
13. Jenkins J.R. Sequence divergence of rainbow trout protamine mRNAs; comparison of coding and non-coding nucleotide sequences in three protamine cDNA plasmids. Nature 1979, 279:809-811.
14. Braun R.E. Packaging paternal chromosomes with protamine. Nat Genet 2001, 28:10-12.
15. Wiencek J.M. New strategies for protein crystal growth. Annu Rev Biomed Eng 1999, 1:505-534.
16. Cudney R., Patel S., Weisgraber K., Newhouse Y., McPherson A. Screening and optimization strategies for macromolecular crystal growth. Acta Crystallogr D Biol Crystallogr 1994, 50:414-423.
17. Chayen N.E., Saridakis E. Protein crystallization: from purified protein to diffraction-quality crystal. Nat Methods 2008, 5:147-153.
18. Carter W.A. Interferon: evidence for subunit structure. Proc Natl Acad Sci U S A 1970, 67:620-628.
19. Judge R.A., Jacobs R.S., Frazier T., Snell E.H., Pusey M.L. The effect of temperature and solution pH on the nucleation of tetragonal lysozyme crystals. Biophys J 1999, 77:1585-1593.
20. Ye H.M., Xu J., Freudenthal J., Kahr B. On the circular birefringence of polycrystalline polymers: polylactide. J Am Chem Soc 2011, 133:13848-13851.
21. Bassett D.C. Polymer spherulites: a modern assessment. J Macromol Sci Phys 2003, 42:227-256.
22. Krebs M.R.H., Bromley E.H.C., Rogers S.S., Donald A.M. The mechanism of amyloid spherulite formation by bovine insulin. Biophys J 2005, 88:2013-2021.
23. Guan J., Ferrell N., James Lee L., Hansford D.J. Fabrication of polymeric microparticles for drug delivery by soft lithography. Biomaterials 2006, 27:4034-4041.
24. Jiang W., Schwendeman S.P. Stabilization of tetanus toxoid encapsulated in PLGA microspheres. Mol Pharm 2008, 5:808-817.
25. Hallas-Moller K., Petersen K., Schlichtkrull J. Crystalline and amorphous insulin-zinc compounds with prolonged action. Science 1952, 116:394-398.
26. Govardhan C., Khalaf N., Jung C.W., Simeone B., Higbie A., Qu S., et al. Novel long-acting crystal formulation of human growth hormone. Pharm Res 2005, 22:1461-1470.
27. Gietz U., Arvinte T., Häner M., Aebi U., Merkle H.P. Formulation of sustained release aqueous Zn-hirudin suspensions. Eur J Pharm Sci 2000, 11:33-41.
28. Zhang P., Chen L., Gu W., Xu Z., Gao Y., Li Y. In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials 2007, 28:1882-1888.
29. Le Ray A.M., Chiffoleau S., Iooss P., Grimandi G., Gouyette A., Daculsi G., et al. Vancomycin encapsulation in biodegradable poly(epsilon-caprolactone) microparticles for bone implantation. Influence of the formulation process on size, drug loading, in vitro release and cytocompatibility. Biomaterials 2003, 24:443-449.
30. Flory P.J. Molecular morphology in semicrystalline polymers. Nature 1978, 272:226-229.
31. Venyaminov Y.S., Yang J.T. Determination of protein secondary structure. Circular dichroism and the conformational analysis of biomolecules 1996, 69-107. Plenum, New York. G.D. Fasman (Ed.).
32. Kelly S.M., Jess T.J., Price N.C. How to study proteins by circular dichroism. Biochim Biophys Acta 2005, 1751:119-139.
33. Frokjaer S., Otzen D.E. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005, 4:298-306.
34. Radhakrishnan R., Walter L.J., Hruza A., Reichert P., Trotta P.P., Nagabhushan T.L., et al. Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure 1996, 4:1453-1463.